NasdaqCM:CELCBiotechs
How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance
In the second quarter of 2026, Celcuity Inc. reported a net loss of US$78.86 million, or US$1.44 per share, with first-half net loss widening to US$131.71 million and loss per share reaching US$2.41, both higher than the same periods a year earlier.
The sharp increase in reported losses underscores how Celcuity’s spending profile is evolving as it advances gedatolisib through clinical development and prepares for potential commercialization.
With these larger recent losses in mind, we’ll now...